TS-01: Der Einstieg in die medikamentöse Therapie des Typ-2 Diabetes

Inhalt: Der Diabetes Mellitus hat in den letzten Jahren im Bereich der Medizin eine zunehmende Bedeutung erlangt. Ziel dieses Programms ist es, Sie in die Ursachen, in die Folgen und in die Therapie des Typ 2-Diabetes einzuführen. Referent: Prof. Dr. med. Stephan Martin Deutsches Diabetes Forschungsinstitut Düsseldorf Erscheinungsdatum: 08.06.2003

Diese Fortbildung ist durch die Bayerische Landesärztekammer für das Modellprojekt 'Freiwilliger Fortbildungsnachweis (Kategorie D)' mit drei CME-Fortbildungspunkten anerkannt.

Linkliste zum Thema:

1. http://www.deutsche-diabetes-gesellschaft.de
   Deutsche Diabetes Gesellschaft
2. http://www.diabecare.com
   Diabetic Supplies
3. http://www.diabetes.org
   American Diabetes Association
4. http://www.diabetes-news.de
   Diabetes Netzwerk Deutschland
5. http://www.diabetes-psychologie.de
   Diabetes und Psychologie e.V.
6. http://www.diabetesweb.de
   diabetesweb.de
7. http://www.med.uni-giessen.de/agda/
   Deutsche Diabetes Gesellschaft AG Diabetes Auge
8. http://www.niddk.nih.gov
   National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)
9. http://www.prosit.de
   Prävention und Disease Management
10. http://www.vdbd.de
    Verband der Diabetes-Beratungs- und Schulungsberufe in Deutschland e.V.
11. http://www.idf.org
    International Diabetes Federation
12. http://www.dge.de
    Deutsche Gesellschaft für Ernährung e.V.
13. http://www.nutrition.org
    The American Society for Nutritional Sciences
14. http://www.diabetesmonitor.com
    Diabetes Monitor
15. http://www.leitlinien.de
    Ärztliches Zentrum für Qualität in der Medizin: leitlinien.de

Literatur zum Thema:

1. Liebl,A, Neiss,A, Spannheimer,A, Reitberger,U, Wagner,T, Görtz,A: Kosten des Typ-2-Diabetes in Deutschland: Ergebnisse der CODE-2-Studie. Dtsch. med. Wschr. 126:585-589, 2001
2. UK Prospective Diabetes Study (UKPDS) Group: Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). The Lancet 352:854-865, 1998
   Medline-Abstract
3. Stumvoll,M, Nurjhan,N, Perriello,G, Dailey,G, Gerich,JE: Metabolic effects of metformin in non-insulin-dependent diabetes mellitus. N. Engl. J. Med. 333:550-554, 1995
   Medline-Abstract
4. Klip,A, Leiter,LA: Cellular mechanism of action of metformin. Diabetes Care 13:696-704, 1990
   Medline-Abstract
5. Garber,AJ, Duncan,TG, Goodman,AM, Mills,DJ, Rohlf,JL: Efficacy of metformin in type II diabetes: results of a double-blind, placebo-controlled, dose-response trial. Am. J. Med. 103:491-497, 1997
   Medline-Abstract
6. Cusi,K, DeFronzo,RA: Metformin: a review of its metabolic effects. Diabetes Reviews 6:89-131, 1998
7. Kay,JP, Alemzadeh,R, Langley,G, D'Angelo,L, Smith,P, Holshouser,S: Beneficial effects of metformin in normoglycemic morbidly obese adolescents. Metabolism 50:1457-1461, 2001
   Medline-Abstract
8. Müller,G: The molecular mechanism of the insulin-mimetic/sensitizing activity of the antidiabetic sulfonylurea drug amaryl. Mol. Med. 6:907-933, 2000
   Medline-Abstract
9. Volk, A, Maerker,E, Rett, K, Häring, HU, Overkamp, D: Glimepirid - effects on peripheral insulin sensitivity (Abstract). Diabetologia 43 (Suppl.1), 2000
10. Holstein,A, Plaschke,A, Egberts,E-H: Lower incidence of severe hypoglycaemia in patients with type 2 diabetes treated with glimepiride versus glibenclamide. Diabetes Metab. Res. Rev. 17:467-473, 2001
    Medline-Abstract
11. Winkler,F, Teich,G, Irsigler,K: Österreichische Glimepirid Multicenter-Studie [Abstract]. Diabetes Stoffwechsel 7 Suppl. 1:68, 1998
12. Scholz,GH, Schneider,K, Knirsch,W, Becker,G: Efficacy and tolerability of Glimepiride in daily practice. Clin. Drug. Invest. 21:597-604, 2001
13. Lebovitz,H: alpha-Glucosidase inhibitors as agents in the treatment of diabetes. Diabetes Reviews 6:132-145, 1998
14. Füchtenbusch,M, Standl,E, Schatz,H: Clinical efficacy of new thiazolidinediones and glinides in the treatment of type 2 diabetes mellitus. Exp. Clin. Endocrinol. Diabetes 108:151-163, 2000
    Medline-Abstract
15. DECODE Study Group on behalf of the European Diabetes Epidemiology Study Group: Will new diagnostic criteria for diabetes mellitus change phenotype of patients with diabetes? Reanalysis of European epidemiological data. BMJ 317:371-375, 1998
    Medline-Abstract
16. Ligueros-Saylan,MKS, Lee,J, Devineni, D, Sunanda,V, Zeig,S, Mcleod,JF: Nateglinid had a low hypoglycemic potential in missed-meal situation (Abstract). Diabetes 49 (Suppl.1), 2000
17. Nolan,JJ, Ludvik,B, Beerdsen,P, Joyce,M, Olefsky,J: Improvement in glucose tolerance and insulin resistance in obese subjects treated with troglitazone. N. Engl. J. Med. 331:1226-1227, 1994
    Medline-Abstract
18. Ehrmann,DA, Schneider,DJ, Sobel,BE, Cavaghan,MK, Imperial,J, Rosenfield,RL, Polonsky,KS: Troglitazone improves defects in insulin action, insulin secretion, ovarian steroidogenesis, and fibrinolysis in women with polycystic ovary syndrome. J. Clin. Endocrinol. Metab. 82:2108-2116, 1997
    Medline-Abstract
19. Berger,J, Bailey,P, Biswas,C, Cullinan,CA, Doebber,TW, Hayes,NS, Saperstein,R, Smith,RG, Leibowitz,MD: Thiazolidinediones produce a conformational change in peroxisomal-proliferator activated receptor-gamma: binding and activaton correlates with antidiabetic action in db/db mice. Endocrinology 137:4189-4195, 1996
    Medline-Abstract
20. Spiegelman,BM: Adipogenic regulator and thiazolidinedion receptor. Diabetes 47:507-514, 1998
    Medline-Abstract
21. Al-Salman,J, Arjomand,H, Kemp,DG, Mittal,M: Hepatocellular injury in a patient receiving rosiglitazone. A case report. Ann. Intern. Med. 132:121-124, 2000
    Medline-Abstract
22. Forman,LM, Simmons,DA, Diamond,RH: Hepatic failure in a patient taking rosiglitazone. Ann. Intern. Med. 132:118-121, 2000
    Medline-Abstract
23. Akazawa,S, Fuyan,S, Ito,M, Kawasaki,E, Eguchi,K: Efficacy of troglitazone on body fat distribution in type 2 diabetes. Diabetes Care 23:1067-1071, 2000
    Medline-Abstract
24. Ludvik,B: Diabetes therapy related to etiology.Indications, uses and side effects of new insulin sensitizers. MMW Fortschr. Med. 142:27-28, 2000
    Medline-Abstract